N-methylnicotinamide API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for N-methylnicotinamide is listed?

Join our notification list by following this page.

List your company
Are you a supplier of N-methylnicotinamide or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for N-methylnicotinamide API 114-33-0?

Description:
Here you will find a list of producers, manufacturers and distributors of N-methylnicotinamide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
N-methylnicotinamide 
Synonyms:
3-(Methylcarbamoyl)pyridine , 3-(N-Methylcarbamoyl)pyridine , N-Methyl nicotineamide , N-Methyl-3-pyridinecarboxamide , N-methylpyridine-3-carboxamide , Nicotinic acid methylamide , Nicotinyl methylamide  
Cas Number:
114-33-0 
DrugBank number:
DB08840 
Unique Ingredient Identifier:
X3I82S5L8I

General Description:

N-methylnicotinamide, identified by CAS number 114-33-0, is a notable compound with significant therapeutic applications. N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation. It is a metabolite of niacinamide/nicotinamide and niacin/nicotinic acid (vitamin B3), and as such N-methylnicotinamide is used to diagnose niacin deficiency by measuring N-methylnicotinamide in the urine.

Indications:

This drug is primarily indicated for: N-methylnicotinamide is an experimental drug with no approved indication. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Route of Elimination:

The elimination of N-methylnicotinamide from the body primarily occurs through: N-methylnicotinamide is excreted in the urine. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Classification:

N-methylnicotinamide belongs to the class of organic compounds known as nicotinamides. These are heterocyclic aromatic compounds containing a pyridine ring substituted at position 3 by a carboxamide group, classified under the direct parent group Nicotinamides. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Pyridines and derivatives class, specifically within the Pyridinecarboxylic acids and derivatives subclass.

Categories:

N-methylnicotinamide is categorized under the following therapeutic classes: Alimentary Tract and Metabolism, Bile and Liver Therapy, Bile Therapy, Drugs that are Mainly Renally Excreted, MATE 1 Substrates, MATE 2 Substrates, MATE substrates, Nicotinic Acids, Preparations for Biliary Tract Therapy, Pyridines. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of N-methylnicotinamide include:

  • Melting Point: 102 - 105 °C or 216 - 221 °F

N-methylnicotinamide is a type of Gastrointestinal Agents


Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).

One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.

Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.

Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.

Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.

In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.